Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Pharmaceutical Co., Ltd.

http://www.nichiiko.co.jp/english

Latest From Nichi-Iko Pharmaceutical Co., Ltd.

A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality Violations

Japan struggles to recover its ever-expanding supply chain for generic drugs after several key players had their production stopped because of a series of GMP violations. As the share of generics grows under government policy, some in the industry argue the problems are deeply rooted in a decades-old pricing system.

Japan Generic Drugs

Nichi-Iko Losses Slow Down At Nine-Month Stage

“The outlook remains uncertain,” one analyst has noted as troubled Japanese manufacturer Nichi-Iko published its nine-month financial results, even as the company’s domestic losses slowed down and its US Sagent unit improved its sales by double-digits.

Sales & Earnings Strategy

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Deals Generic Drugs

Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss

Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.

Quality Supply Chain
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Elmed Eisai Co., Ltd
    • Nichi-Iko Medical Practice Institution Co., Ltd.
    • Yakuhan Pharmaceutical Co., Ltd.
    • Nichi-Iko Pharma Tech Co., Ltd.
    • Omega Laboratories Limited
    • Sagent Pharmaceuticals Inc.
    • Nihon Iyakuhin Kogyo Co., Ltd.
UsernamePublicRestriction

Register